Fludara

DRUG5 trials

Conditions

Acute Myeloid LeukemiaCancerLiver CancerMyelodysplastic SyndromeNeuroblastomaRelapse/Refractory Multiple Myeloma

Phase 1

3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN

Active, not recruitingNCT01822652

Baylor College of MedicineNeuroblastoma

Start: 2013-08-01End: 2030-10-01Updated: 2026-04-06

Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)

Active, not recruitingNCT02932956

Baylor College of MedicineLiver Cancer

Start: 2018-12-17End: 2037-02-28Updated: 2025-09-19

Adoptive Cell Therapy Across Cancer Diagnoses

CompletedNCT03296137

Inge Marie SvaneCancer

Start: 2017-10-13End: 2020-07-01Updated: 2024-10-26

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

RecruitingNCT04167696

Celyad Oncology SAAcute Myeloid Leukemia, Myelodysplastic Syndrome

Start: 2019-11-25End: 2035-02-28Target: 27Updated: 2020-06-09

Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

Active, not recruitingNCT04613557

Celyad Oncology SARelapse/Refractory Multiple Myeloma

Start: 2020-11-16End: 2037-02-28Updated: 2023-08-31

2025-09-15

Clinical Proof-of-Concept of a Non-Gene Editing Technology Using miRNA-Based shRNA to Engineer Allogeneic CAR T-Cells

International Journal of Molecular Sciences2025-02-159 citations

Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers.

2024-11-27110 citations

Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers

Journal for ImmunoTherapy of Cancer2024-05-0143 citations

285 Proof-of-concept of a non-gene editing technology using shRNA down-regulation to engineer and optimize CAR T-cell functionality

Regular and Young Investigator Award Abstracts2023-10-314 citations

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab

Journal for ImmunoTherapy of Cancer2023-05-0131 citations

Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform

Blood2021-11-0523 citations

Co-Expression of an shRNA Targeting MICA/Micb Improves the Clinical Activity of a NKG2D-Based CAR T in Patients with Relapsed / Refractory AML/MDS

Blood2021-11-0510 citations

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types

Journal for ImmunoTherapy of Cancer2021-10-0161 citations

First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Blood2020-11-0420 citations

A phase I clinical trial using armored GPC3 CAR T cells for children with relapsed/refractory liver tumors.

Journal of Clinical Oncology2019-05-2010 citations

New Immunotherapy Approaches Attack Pediatric Cancers

Oncology Times2019-03-28

Fludara

Sponsors

Conditions

Phase 1

Related Papers